Quad

This page shows the latest Quad news and features for those working in and with pharma, biotech and healthcare.

ViiV takes two-drug cocktail for first-line HIV into phase III

HIV therapies that combine multiple drugs into one tablet such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and Gilead's Quad product (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) are expected to be

Latest news

Aurobindo joins Patent Pool

Quad (a combination of the three drugs and tenofovir).
Gilead agrees HIV patent pool deal

as a combination pill to be called Quad.
Gilead's HIV drug meets phase III endpoint

Gilead is studying the use of elvitegravir as part of a separate investigational fixed-dose, single-tablet "Quad" regimen. ... Quad pill," said Dr Norbert Bischofberger, executive vice president, R&D and chief scientific officer, Gilead Sciences. .
A competitive edge

An exciting new four-in-one fixed-dose tablet, known as "Quad", has been developed by Gilead Sciences. ... CROI. These results demonstrated that the Quad regimen exhibited antiretroviral activity comparable to that of Atripla.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...